RU2503448C2 - Применение каннабиноидов в комбинации с антипсихотическим лекарственным средством - Google Patents

Применение каннабиноидов в комбинации с антипсихотическим лекарственным средством Download PDF

Info

Publication number
RU2503448C2
RU2503448C2 RU2010132649/15A RU2010132649A RU2503448C2 RU 2503448 C2 RU2503448 C2 RU 2503448C2 RU 2010132649/15 A RU2010132649/15 A RU 2010132649/15A RU 2010132649 A RU2010132649 A RU 2010132649A RU 2503448 C2 RU2503448 C2 RU 2503448C2
Authority
RU
Russia
Prior art keywords
aripiprazole
cbd
thcv
disorder
combination
Prior art date
Application number
RU2010132649/15A
Other languages
English (en)
Russian (ru)
Other versions
RU2010132649A (ru
Inventor
Тецуро Кикути
Кендзи МАЕДА
Джеффри Гай
Филип РОБСОН
Колин Стотт
Original Assignee
ДжиДаблЮ ФАРМА ЛИМИТЕД
Оцука Фармасьютикал Ко., Лимитед
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=39144704&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=RU2503448(C2) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by ДжиДаблЮ ФАРМА ЛИМИТЕД, Оцука Фармасьютикал Ко., Лимитед filed Critical ДжиДаблЮ ФАРМА ЛИМИТЕД
Publication of RU2010132649A publication Critical patent/RU2010132649A/ru
Application granted granted Critical
Publication of RU2503448C2 publication Critical patent/RU2503448C2/ru

Links

Images

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/05—Phenols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/498—Pyrazines or piperazines ortho- and peri-condensed with carbocyclic ring systems, e.g. quinoxaline, phenazine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/658—Medicinal preparations containing organic active ingredients o-phenolic cannabinoids, e.g. cannabidiol, cannabigerolic acid, cannabichromene or tetrahydrocannabinol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K36/00—Medicinal preparations of undetermined constitution containing material from algae, lichens, fungi or plants, or derivatives thereof, e.g. traditional herbal medicines
    • A61K36/18—Magnoliophyta (angiosperms)
    • A61K36/185—Magnoliopsida (dicotyledons)
    • A61K36/348—Cannabaceae
    • A61K36/3482—Cannabis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/08—Antiepileptics; Anticonvulsants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/18—Antipsychotics, i.e. neuroleptics; Drugs for mania or schizophrenia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/22—Anxiolytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/24—Antidepressants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P27/00—Drugs for disorders of the senses
    • A61P27/02—Ophthalmic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Natural Medicines & Medicinal Plants (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Botany (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Medical Informatics (AREA)
  • Biotechnology (AREA)
  • Alternative & Traditional Medicine (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Ophthalmology & Optometry (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Hematology (AREA)
  • Obesity (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Diabetes (AREA)
  • Child & Adolescent Psychology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Plant Substances (AREA)
RU2010132649/15A 2008-01-04 2008-12-17 Применение каннабиноидов в комбинации с антипсихотическим лекарственным средством RU2503448C2 (ru)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
GB0800390A GB2456183A (en) 2008-01-04 2008-01-04 Anti-psychotic composition comprising cannabinoids and anti-psychotic medicament
GB0800390.7 2008-01-04
PCT/GB2008/004217 WO2009087351A1 (en) 2008-01-04 2008-12-17 Use of cannabinoids in combination with an anti-psychotic medicament

Publications (2)

Publication Number Publication Date
RU2010132649A RU2010132649A (ru) 2012-02-10
RU2503448C2 true RU2503448C2 (ru) 2014-01-10

Family

ID=39144704

Family Applications (1)

Application Number Title Priority Date Filing Date
RU2010132649/15A RU2503448C2 (ru) 2008-01-04 2008-12-17 Применение каннабиноидов в комбинации с антипсихотическим лекарственным средством

Country Status (25)

Country Link
US (1) US9017737B2 (cg-RX-API-DMAC7.html)
EP (3) EP3095452B1 (cg-RX-API-DMAC7.html)
JP (1) JP5409650B2 (cg-RX-API-DMAC7.html)
KR (1) KR101631518B1 (cg-RX-API-DMAC7.html)
CN (1) CN101939017B (cg-RX-API-DMAC7.html)
AR (1) AR070063A1 (cg-RX-API-DMAC7.html)
AU (1) AU2008346285B2 (cg-RX-API-DMAC7.html)
BR (1) BRPI0821461A8 (cg-RX-API-DMAC7.html)
CA (1) CA2708921C (cg-RX-API-DMAC7.html)
CL (1) CL2008003902A1 (cg-RX-API-DMAC7.html)
CO (1) CO6290695A2 (cg-RX-API-DMAC7.html)
ES (3) ES2750728T3 (cg-RX-API-DMAC7.html)
GB (3) GB2456183A (cg-RX-API-DMAC7.html)
HU (2) HUE047214T2 (cg-RX-API-DMAC7.html)
IL (1) IL206784A0 (cg-RX-API-DMAC7.html)
MX (1) MX2010007073A (cg-RX-API-DMAC7.html)
NZ (1) NZ586648A (cg-RX-API-DMAC7.html)
PE (2) PE20141249A1 (cg-RX-API-DMAC7.html)
PL (2) PL2609928T3 (cg-RX-API-DMAC7.html)
PT (2) PT3095452T (cg-RX-API-DMAC7.html)
RU (1) RU2503448C2 (cg-RX-API-DMAC7.html)
TW (2) TWI519299B (cg-RX-API-DMAC7.html)
UA (1) UA103472C2 (cg-RX-API-DMAC7.html)
WO (1) WO2009087351A1 (cg-RX-API-DMAC7.html)
ZA (1) ZA201005443B (cg-RX-API-DMAC7.html)

Cited By (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
RU2746000C2 (ru) * 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US11458111B2 (en) 2017-09-26 2022-10-04 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US11571397B2 (en) 2018-05-11 2023-02-07 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)
US11634377B2 (en) 2015-12-22 2023-04-25 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
US11673852B2 (en) 2015-12-22 2023-06-13 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
US12097206B2 (en) 2013-05-03 2024-09-24 Katholieke Universiteit Leuven Method for the treatment of Dravet Syndrome
US12144787B2 (en) 2018-11-19 2024-11-19 Zogenix International Limited Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)

Families Citing this family (81)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7053092B2 (en) 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
GB2377218A (en) * 2001-05-04 2003-01-08 Gw Pharmaceuticals Ltd Process and apparatus for extraction of active substances and enriched extracts from natural products
AR033485A1 (es) 2001-09-25 2003-12-26 Otsuka Pharma Co Ltd Sustancia medicinal de aripiprazol de baja higroscopicidad y proceso para la preparacion de la misma
GB0425248D0 (en) 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
US9168278B2 (en) 2004-11-16 2015-10-27 Gw Pharma Limited Use for cannabinoid
GB2459637B (en) * 2008-01-21 2012-06-06 Gw Pharma Ltd New use for cannabinoids
GB2471523A (en) 2009-07-03 2011-01-05 Gw Pharma Ltd Use of tetrahydrocannibivarin (THCV) and optionally cannabidiol (CBD) in the treatment of epilepsy
GB2478595B (en) * 2010-03-12 2018-04-04 Gw Pharma Ltd Phytocannabinoids in the treatment of glioma
EP2551255B1 (en) * 2010-03-26 2017-11-08 Vivacell Biotechnology España, S.L Cannabinoid quinone derivatives
TWI583374B (zh) 2010-03-30 2017-05-21 Ｇｗ伐瑪有限公司 使用植物大麻素次大麻二酚（ｃｂｄｖ）來治療癲癇之用途
US8445034B1 (en) 2010-11-02 2013-05-21 Albert L Coles, Jr. Systems and methods for producing organic cannabis tincture
EP2654864B1 (en) 2010-12-22 2020-10-28 Syqe Medical Ltd. System for drug delivery
GB2487712B (en) 2011-01-04 2015-10-28 Otsuka Pharma Co Ltd Use of the phytocannabinoid cannabidiol (CBD) in combination with a standard anti-epileptic drug (SAED) in the treatment of epilepsy
GB2495118B (en) 2011-09-29 2016-05-18 Otsuka Pharma Co Ltd A pharmaceutical composition comprising the phytocannabinoids cannabidivarin (CBDV) and cannabidiol (CBD)
JP6562912B2 (ja) * 2013-06-26 2019-08-21 アムジェン インコーポレイテッド Ｃｂ１受容体抗原結合タンパク質及びその使用
ES2610988T3 (es) 2013-10-29 2017-05-04 Echo Pharmaceuticals B.V. Comprimido que contiene cannabidiol, método para su producción y uso de tal comprimido en el tratamiento oral de trastornos psicóticos o de ansiedad
AU2014340710B2 (en) 2013-10-29 2019-08-22 Echo Pharmaceuticals B.V. Compressed tablet containing delta 9-tetrahydrocannabinol, method for its manufacture and use of such tablet in oral treatment
GB2530001B (en) 2014-06-17 2019-01-16 Gw Pharma Ltd Use of cannabidiol in the reduction of convulsive seizure frequency in treatment-resistant epilepsy
GB2527599A (en) 2014-06-27 2015-12-30 Gw Pharma Ltd Use of 7-OH-Cannabidiol (7-OH-CBD) and/or 7-OH-Cannabidivarin (7-OH-CBDV) in the treatment of epilepsy
JP6980388B2 (ja) 2014-06-30 2021-12-15 サイケ メディカル リミテッドSyqe Medical Ltd. 気流調節吸入装置
US11298477B2 (en) 2014-06-30 2022-04-12 Syqe Medical Ltd. Methods, devices and systems for pulmonary delivery of active agents
EP3539599B1 (en) 2014-06-30 2021-10-20 Syqe Medical Ltd. Drug dose cartridge for an inhaler device
IL294077A (en) 2014-06-30 2022-08-01 Syqe Medical Ltd Method and device for vaporizing and inhaling substances
JP6747988B2 (ja) * 2014-06-30 2020-08-26 サイケ メディカル リミテッドＳｙｑｅ Ｍｅｄｉｃａｌ Ｌｔｄ． 活性薬剤肺送達のための方法、装置及びシステム
IL273507B2 (en) 2014-06-30 2024-06-01 Syqe Medical Ltd Methods, devices and systems for administering active substances through the lungs
EP3160565B1 (en) 2014-06-30 2021-08-18 Syqe Medical Ltd. Devices and systems for pulmonary delivery of active agents
GB2531282A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2531281A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
GB2531278A (en) 2014-10-14 2016-04-20 Gw Pharma Ltd Use of cannabidiol in the treatment of intractable epilepsy
US9539295B2 (en) 2014-12-05 2017-01-10 Bradley Michael Bohus Cannabidiol (CBD) enriched alcohol
GB2539472A (en) 2015-06-17 2016-12-21 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
US9585867B2 (en) 2015-08-06 2017-03-07 Charles Everett Ankner Cannabinod formulation for the sedation of a human or animal
GB2541191A (en) 2015-08-10 2017-02-15 Gw Pharma Ltd Use of cannabinoids in the treatment of epilepsy
GB2542155B (en) 2015-09-09 2018-08-01 Gw Pharma Ltd Use of cannabidiol in the treatment of mental disorders
WO2017118980A1 (en) 2016-01-06 2017-07-13 Syqe Medical Ltd. Low dose therapeutic treatment
GB2548873B (en) 2016-03-31 2020-12-02 Gw Res Ltd Use of Cannabidiol in the Treatment of SturgeWeber Syndrome
US10499584B2 (en) 2016-05-27 2019-12-10 New West Genetics Industrial hemp Cannabis cultivars and seeds with stable cannabinoid profiles
AU2017290107A1 (en) 2016-06-29 2019-01-17 CannScience Innovations Inc. Decarboxylated cannabis resins, uses thereof and methods of making same
GB2551986A (en) 2016-07-01 2018-01-10 Gw Res Ltd Parenteral formulations
GB2551987A (en) 2016-07-01 2018-01-10 Gw Res Ltd Oral cannabinoid formulations
US20180021326A1 (en) 2016-07-23 2018-01-25 Paul Edward Stamets Compositions and methods for enhancing neuroregeneration and cognition by combining mushroom extracts containing active ingredients psilocin or psilocybin with erinacines or hericenones enhanced with niacin
US20210069170A1 (en) 2016-07-23 2021-03-11 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
US11701348B1 (en) 2016-07-23 2023-07-18 Turtle Bear Holdings, Llc Psilocybin compositions
GB2553139A (en) 2016-08-25 2018-02-28 Gw Res Ltd Use of cannabinoids in the treatment of multiple myeloma
US10835501B2 (en) 2016-10-01 2020-11-17 Indication Bioscience Llc Pharmaceutical compositions comprising a statin and a cannabinoid and uses thereof
CN108078984B (zh) * 2016-11-23 2020-11-20 汉义生物科技（北京）有限公司 5-羟色胺和去甲肾上腺素再摄取抑制剂与大麻二酚的组合物及其应用
CN108143726B (zh) * 2016-12-02 2020-05-08 汉义生物科技（北京）有限公司 大麻二酚与5-ht2a受体拮抗剂及5-ht再摄取抑制剂的药物组合物及其用途
GB2557921A (en) 2016-12-16 2018-07-04 Gw Res Ltd Use of cannabinoids in the treatment of angelman syndrome
WO2018115001A1 (en) 2016-12-20 2018-06-28 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
RU2764443C2 (ru) 2016-12-20 2022-01-17 Лтс Ломанн Терапи-Систем Аг Трансдермальная терапевтическая система, содержащая азенапин и полисилоксан или полиизобутилен
EP3579832A4 (en) * 2017-02-09 2020-12-30 Caamtech, LLC COMPOSITIONS AND PROCESSES INCLUDING A PSILOCYBIN DERIVATIVE
US11974984B2 (en) 2017-02-09 2024-05-07 Caamtech, Inc. Compositions and methods comprising a combination of serotonergic drugs
US12414936B2 (en) 2017-02-09 2025-09-16 Caamtech, Inc. Compositions comprising a serotonergic tryptamine compound
GB2559774B (en) 2017-02-17 2021-09-29 Gw Res Ltd Oral cannabinoid formulations
GB2560019A (en) 2017-02-27 2018-08-29 Gw Res Ltd Use of cannabinoids in the treatment of leukaemia
GB2564383B (en) 2017-06-23 2021-04-21 Gw Res Ltd Use of cannabidiol in the treatment of tumours assoicated with Tuberous Sclerosis Complex
CN110799180A (zh) 2017-06-26 2020-02-14 罗曼治疗系统股份公司 含阿塞那平和硅氧烷丙烯酸杂化聚合物的经皮治疗系统
CN107469087A (zh) * 2017-09-10 2017-12-15 孙永丽 用于治疗精神病的制剂
WO2019099745A1 (en) * 2017-11-16 2019-05-23 CaaMTech, LLC Compositions comprising a psilocybin derivative and a cannabinoid
GB2568929A (en) 2017-12-01 2019-06-05 Gw Res Ltd Use of cannabinoids in the treatment of epilepsy
WO2019113079A1 (en) 2017-12-05 2019-06-13 Sunovion Pharmaceuticals Inc. Nonracemic mixtures and uses thereof
CN112236138B (zh) 2017-12-05 2024-05-31 赛诺维信制药公司 晶体形式及其制备方法
GB2569961B (en) 2018-01-03 2021-12-22 Gw Res Ltd Pharmaceutical
CA3091776C (en) * 2018-02-20 2021-12-28 Supera Pharmaceuticals, Inc. Genetically modified cannabis sativa plants and modified cannabinoid compounds for treatment of substance addiction and other disorders
CN112533593A (zh) 2018-06-20 2021-03-19 罗曼治疗系统股份公司 含有阿塞那平的透皮治疗系统
AU2019291060B2 (en) 2018-06-20 2024-09-05 Lts Lohmann Therapie-Systeme Ag Transdermal therapeutic system containing asenapine
WO2020188569A1 (en) * 2019-03-20 2020-09-24 Bol Pharma Ltd. Methods and compositions for preventing or treating weight gain caused by psychiatric drugs
SG11202113266YA (en) 2019-06-04 2021-12-30 Sunovion Pharmaceuticals Inc Modified release formulations and uses thereof
GB201910389D0 (en) 2019-07-19 2019-09-04 Gw Pharma Ltd Novel compounds, methods for their manufacture, and uses thereof
GB2588576A (en) 2019-08-27 2021-05-05 Gw Res Ltd Use of cannabinoids in the treatment of dyskinesia associated with Parkinson's disease
CA3158059A1 (en) 2019-11-19 2021-05-27 Paul Edward Stamets Tryptamine compositions for enhancing neurite outgrowth
GB201916849D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916846D0 (en) 2019-11-19 2020-01-01 Gw Res Ltd Cannabidiol-type cannabinoid compound
GB201916974D0 (en) 2019-11-21 2020-01-08 Gw Res Ltd Cannabidol-type cannabinoid compound
GB202002754D0 (en) 2020-02-27 2020-04-15 Gw Res Ltd Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
CA3187303A1 (en) 2020-07-28 2022-02-03 Impello Biosciences, Inc. Methods and compositions for altering secondary metabolites in plants
US11160757B1 (en) 2020-10-12 2021-11-02 GW Research Limited pH dependent release coated microparticle cannabinoid formulations
US12029718B2 (en) 2021-11-09 2024-07-09 Cct Sciences, Llc Process for production of essentially pure delta-9-tetrahydrocannabinol
US20240009133A1 (en) * 2020-11-16 2024-01-11 Orcosa Inc. Methods of treating autoimmune or inflammatory conditions with cannabidiol or its derivatives/analogs
US11337934B1 (en) 2021-04-08 2022-05-24 Lanny Leo Johnson Compositions including a cannabinoid and protocatechuic acid
US11977085B1 (en) 2023-09-05 2024-05-07 Elan Ehrlich Date rape drug detection device and method of using same

Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095899A2 (en) * 2000-06-16 2001-12-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising cannabidiol derivatives
WO2003105800A2 (de) * 2002-06-14 2003-12-24 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
WO2006054057A2 (en) * 2004-11-16 2006-05-26 Gw Pharma Limited New use for cannabinoid
RU2281941C2 (ru) * 2001-03-22 2006-08-20 Солвей Фармасьютикалс Б.В. Производные 4,5-дигидро-1h-пиразола, обладающие cb1-антагонистической активностью
RU2295960C2 (ru) * 2001-04-25 2007-03-27 Бристол-Маерс Сквибб Компани Фармацевтический раствор арипипразола для орального применения

Family Cites Families (23)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5006528A (en) 1988-10-31 1991-04-09 Otsuka Pharmaceutical Co., Ltd. Carbostyril derivatives
US7053092B2 (en) * 2001-01-29 2006-05-30 Otsuka Pharmaceutical Co., Ltd. 5-HT1a receptor subtype agonist
AR032641A1 (es) 2001-01-29 2003-11-19 Otsuka Pharma Co Ltd Agonista de subtipo de receptor 5-ht 1a.
US20050154202A1 (en) * 2002-04-05 2005-07-14 Hagmann William K. Substituted aryl amides
GB2392093B (en) * 2002-08-14 2006-03-08 Gw Pharma Ltd Pharmaceutical formulations
GB0222077D0 (en) * 2002-09-23 2002-10-30 Gw Pharma Ltd Methods of preparing cannabinoids from plant material
CN1989968B (zh) 2002-12-27 2011-05-11 大塚制药株式会社 用于治疗情绪障碍的喹诺酮衍生物和5-羟色胺再摄取抑制剂
MXPA05012538A (es) * 2003-05-23 2006-02-22 Otsuka Pharma Co Ltd Derivados de carbostirilo y estabilizantes del estado de animo para trastornos del mismo.
US8470874B2 (en) 2003-06-24 2013-06-25 Gw Pharma Limited Pharmaceutical compositions comprising cannabichromene type compounds
RU2006110545A (ru) * 2003-09-02 2007-10-10 Зольвай Фармасьютикалз Гмбх (De) Новое медицинское применение избирательных антагонистов св1-рецептора
AU2004273865A1 (en) * 2003-09-18 2005-03-31 Merck & Co., Inc. Substituted sulfonamides
AR045651A1 (es) * 2003-09-19 2005-11-02 Solvay Pharm Bv Derivados de tiazol como moduladores del receptor de cannabinoide
AU2004309365A1 (en) * 2003-12-19 2005-07-14 Bristol-Myers Squibb Company Azabicyclic heterocycles as cannabinoid receptor modulators
GB0425248D0 (en) * 2004-11-16 2004-12-15 Gw Pharma Ltd New use for cannabinoid
FR2882931B1 (fr) * 2005-03-14 2007-05-18 Sanofi Aventis Sa Compositions pharmaceutiques contenant en association un compose antagoniste des recepteurs aux cannabinoidess et un agent antipsychotique
PE20071092A1 (es) 2005-12-08 2007-12-10 Aventis Pharma Inc Composicion farmaceutica que comprende un antagonista de cb1 y un agente antisicotico
WO2007136571A1 (en) * 2006-05-15 2007-11-29 Merck & Co., Inc. Pro-drugs of tertiary alcohols
GB2438682A (en) * 2006-06-01 2007-12-05 Gw Pharma Ltd New use for cannabinoids
EP1867308B1 (en) 2006-06-12 2010-10-20 Camp Scandinavia Ab Frame for a hyperextension brace
US8481085B2 (en) 2006-06-15 2013-07-09 Gw Pharma Limited Pharmaceutical compositions comprising cannabigerol
GB2439393B (en) * 2006-06-23 2011-05-11 Gw Pharma Ltd Cannabinoids for use in the treatment of neuropathic pain
WO2008133884A2 (en) * 2007-04-23 2008-11-06 Combinatorx, Incorporated Methods and compositions for the treatment of neurodegenerative disorders
US8889076B2 (en) * 2008-12-29 2014-11-18 Uop Llc Fluid catalytic cracking system and process

Patent Citations (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095899A2 (en) * 2000-06-16 2001-12-20 Yissum Research Development Company Of The Hebrew University Of Jerusalem Pharmaceutical compositions comprising cannabidiol derivatives
RU2281941C2 (ru) * 2001-03-22 2006-08-20 Солвей Фармасьютикалс Б.В. Производные 4,5-дигидро-1h-пиразола, обладающие cb1-антагонистической активностью
RU2295960C2 (ru) * 2001-04-25 2007-03-27 Бристол-Маерс Сквибб Компани Фармацевтический раствор арипипразола для орального применения
WO2003105800A2 (de) * 2002-06-14 2003-12-24 Lts Lohmann Therapie-Systeme Ag Filmförmige mucoadhäsive darreichungsformen zur verabreichung von cannabis-wirkstoffen
WO2006017892A1 (en) * 2004-08-16 2006-02-23 Northern Sydney And Central Coast Area Health Service Methods for improving cognitive functioning
WO2006054057A2 (en) * 2004-11-16 2006-05-26 Gw Pharma Limited New use for cannabinoid

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Cassano Giovan В, Fagiolini Andrea и др. / Aripiprazole in the Treatment of Schizophrenia: A Consensus Report produced by Schizophrenia Experts in Italy / Clinical Drug Investigation / 2007, Volume 27, Issue 1, page 1-13. *

Cited By (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US12097206B2 (en) 2013-05-03 2024-09-24 Katholieke Universiteit Leuven Method for the treatment of Dravet Syndrome
US11634377B2 (en) 2015-12-22 2023-04-25 Zogenix International Limited Fenfluramine compositions and methods of preparing the same
US11673852B2 (en) 2015-12-22 2023-06-13 Zogenix International Limited Metabolism resistant fenfluramine analogs and methods of using the same
RU2746000C2 (ru) * 2016-08-24 2021-04-05 Зодженикс Интернэшнл Лимитед Состав для ингибирования образования агонистов 5-ht2b и способы его применения
US11040018B2 (en) 2016-08-24 2021-06-22 Zogenix International Limited Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
US11406606B2 (en) 2016-08-24 2022-08-09 Zogenix International Limited Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
US11759440B2 (en) 2016-08-24 2023-09-19 Zogenix International Limited Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
US11786487B2 (en) 2016-08-24 2023-10-17 Zogenix International Limited Formulation for inhibiting formation of 5-HT2B agonists and methods of using same
US11458111B2 (en) 2017-09-26 2022-10-04 Zogenix International Limited Ketogenic diet compatible fenfluramine formulation
US11571397B2 (en) 2018-05-11 2023-02-07 Zogenix International Limited Compositions and methods for treating seizure-induced sudden death
US12144787B2 (en) 2018-11-19 2024-11-19 Zogenix International Limited Method of treating patients with a mutation in cyclin-dependent kinase-like 5 (CDKL5)
US11612574B2 (en) 2020-07-17 2023-03-28 Zogenix International Limited Method of treating patients infected with severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)

Also Published As

Publication number Publication date
PE20141249A1 (es) 2014-10-03
BRPI0821461A8 (pt) 2018-04-03
EP3095452A1 (en) 2016-11-23
TW200936127A (en) 2009-09-01
CA2708921C (en) 2018-03-20
HUE047214T2 (hu) 2020-04-28
IL206784A0 (en) 2010-12-30
PT3095452T (pt) 2019-10-30
NZ586648A (en) 2012-12-21
EP2609928B1 (en) 2019-07-17
GB201012953D0 (en) 2010-09-15
CN101939017B (zh) 2016-08-17
TW201436791A (zh) 2014-10-01
EP2249848B1 (en) 2016-05-18
JP2011508765A (ja) 2011-03-17
CN101939017A (zh) 2011-01-05
AU2008346285A1 (en) 2009-07-16
PE20091361A1 (es) 2009-09-23
EP2609928A3 (en) 2013-12-18
AR070063A1 (es) 2010-03-10
ES2574155T3 (es) 2016-06-15
US9017737B2 (en) 2015-04-28
ES2750728T3 (es) 2020-03-26
GB2456183A (en) 2009-07-08
RU2010132649A (ru) 2012-02-10
GB0800390D0 (en) 2008-02-20
JP5409650B2 (ja) 2014-02-05
EP2249848A1 (en) 2010-11-17
PL3095452T3 (pl) 2020-05-18
GB201216932D0 (en) 2012-11-07
CA2708921A1 (en) 2009-07-16
AU2008346285B2 (en) 2015-04-02
CL2008003902A1 (es) 2009-07-24
ZA201005443B (en) 2011-04-28
TWI519299B (zh) 2016-02-01
HUE046780T2 (hu) 2020-03-30
GB2468828A (en) 2010-09-22
EP2609928A2 (en) 2013-07-03
ES2751117T3 (es) 2020-03-30
KR101631518B1 (ko) 2016-06-24
UA103472C2 (uk) 2013-10-25
MX2010007073A (es) 2010-12-02
PT2609928T (pt) 2019-10-29
EP3095452B1 (en) 2019-07-17
WO2009087351A1 (en) 2009-07-16
GB2468828B (en) 2012-11-07
US20110038958A1 (en) 2011-02-17
BRPI0821461A2 (pt) 2015-06-16
CO6290695A2 (es) 2011-06-20
PL2609928T3 (pl) 2020-06-01
KR20100113099A (ko) 2010-10-20

Similar Documents

Publication Publication Date Title
RU2503448C2 (ru) Применение каннабиноидов в комбинации с антипсихотическим лекарственным средством
US11406623B2 (en) Methods of treating tuberous sclerosis complex with cannabidiol and everolimus
JP2020111610A (ja) 結節性硬化症の治療におけるカンナビジオールの使用
JP2018521042A (ja) てんかんの治療におけるカンナビノイドの使用
US11173140B2 (en) Dosing regimens of PKC activators
WO2015198077A1 (en) 7-hydroxy cannabidiol (7-oh-cbd) for use in the treatment of non-alcoholic fatty liver disease (nafld)
US20110112187A1 (en) Use Of Tranilast And Derivatives Thereof For The Therapy Of Neurological Conditions
HK1186416B (en) Use of cannabinoids in combination with aripiprazole
HK1148672B (en) Use of cannabinoids in combination with aripiprazole
HK1186416A (en) Use of cannabinoids in combination with aripiprazole
Vgenopoulou et al. Melatonin levels in Alzheimer disease

Legal Events

Date Code Title Description
PD4A Correction of name of patent owner
PC41 Official registration of the transfer of exclusive right

Effective date: 20200117